Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues…

Profound sees record revenues in Q3-2025; up 84-87% YoY with higher gross margin - BioTuesdays

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that it anticipates total revenues for the third quarter of 2025 to be in the approximate range of $5.2 million to $5.3 million, representing YoY revenue growth of between 84% and 87%. This compares favorably to consensus analyst estimates of $4.7 million in revenue for the quarter. Gross margin is expected to be approximately 72% for the third quarter of 2025, compared to 64% in the prior year…